1. Home
  2. IMMP vs PMO Comparison

IMMP vs PMO Comparison

Compare IMMP & PMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMP
  • PMO
  • Stock Information
  • Founded
  • IMMP 1987
  • PMO 1993
  • Country
  • IMMP Australia
  • PMO United States
  • Employees
  • IMMP N/A
  • PMO N/A
  • Industry
  • IMMP Biotechnology: Pharmaceutical Preparations
  • PMO Finance Companies
  • Sector
  • IMMP Health Care
  • PMO Finance
  • Exchange
  • IMMP Nasdaq
  • PMO Nasdaq
  • Market Cap
  • IMMP 211.1M
  • PMO 287.4M
  • IPO Year
  • IMMP N/A
  • PMO N/A
  • Fundamental
  • Price
  • IMMP $1.86
  • PMO $9.99
  • Analyst Decision
  • IMMP Buy
  • PMO
  • Analyst Count
  • IMMP 2
  • PMO 0
  • Target Price
  • IMMP $8.50
  • PMO N/A
  • AVG Volume (30 Days)
  • IMMP 648.0K
  • PMO 99.0K
  • Earning Date
  • IMMP 05-16-2025
  • PMO 01-01-0001
  • Dividend Yield
  • IMMP N/A
  • PMO 4.10%
  • EPS Growth
  • IMMP N/A
  • PMO N/A
  • EPS
  • IMMP N/A
  • PMO 0.42
  • Revenue
  • IMMP $3,019,249.00
  • PMO N/A
  • Revenue This Year
  • IMMP $11.25
  • PMO N/A
  • Revenue Next Year
  • IMMP $10.22
  • PMO N/A
  • P/E Ratio
  • IMMP N/A
  • PMO $24.38
  • Revenue Growth
  • IMMP 24.11
  • PMO N/A
  • 52 Week Low
  • IMMP $1.32
  • PMO $8.57
  • 52 Week High
  • IMMP $3.34
  • PMO $10.68
  • Technical
  • Relative Strength Index (RSI)
  • IMMP 53.43
  • PMO 55.88
  • Support Level
  • IMMP $1.44
  • PMO $9.84
  • Resistance Level
  • IMMP $2.71
  • PMO $10.03
  • Average True Range (ATR)
  • IMMP 0.17
  • PMO 0.10
  • MACD
  • IMMP 0.05
  • PMO 0.04
  • Stochastic Oscillator
  • IMMP 29.75
  • PMO 100.00

About IMMP Immutep Limited

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

About PMO Putnam Municipal Opportunities Trust

Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.

Share on Social Networks: